Atherosclerosis is a chronic disease of the intima of medium-sized and large arteries in which the retention of lipoproteins containing apolipoprotein B initiates a cellular and immune response that leads to plaque formation. The pathological tissue contains, in varying proportions, extracellular lipids, cholesterol-laden cells, fibrous matrix, necrotic debris, and mineral deposits. The disease mainly affects the aorta, coronary arteries, carotid arteries, lower-limb arteries, and visceral circulation; its distribution is multifocal and depends on both systemic exposures and local vessel characteristics. Clinical consequences result from restricted blood flow, thrombosis on the plaque surface, embolization and, in some locations, compromised integrity of the vessel wall.
The term is not synonymous with arteriosclerosis, a broader designation encompassing several forms of arterial thickening and stiffening. Medial calcification, common in diabetes and advanced kidney disease, may coexist with atherosclerosis but is not the same as an intimal atheroma. Likewise, elevated blood cholesterol and the presence of a plaque are distinct conditions: the former describes a causal exposure, whereas the latter is a structural lesion. Similarly, an artery containing plaques may retain a wide lumen, while vascular narrowing may result from processes other than atherosclerosis. These distinctions guide both the interpretation of investigations and the choice of treatment.
The anatomical prevalence of the disease far exceeds that of its symptomatic manifestations. In the PESA cohort, consisting of 4,184 apparently healthy adults aged 40–54 years, subclinical atherosclerosis, defined by plaques in the vascular territories examined and/or coronary artery calcium, was present in 63% of participants. This finding documents the frequency of the silent phase in that particular cohort and with that imaging protocol; it is not an estimate that can automatically be extrapolated to the Italian population or all age groups. Clinically, ischemic heart disease, a proportion of ischemic strokes, and peripheral artery disease are the principal manifestations of the atherosclerotic burden. Overall cardiovascular mortality cannot be attributed entirely to atherosclerosis, because it also includes hypertensive, valvular, and myocardial diseases and other causes.
The disease generally evolves over decades. Exposure to atherogenic lipoproteins acts through the combination of concentration and duration, while blood pressure, smoking, metabolic disturbances, and inflammation modify vessel-wall susceptibility and the likelihood of events. Consequently, a lipid measurement obtained today cannot, by itself, reconstruct a patient's entire history. Documented disease requires an assessment of the affected vascular territory and of systemic risk: treating a stenosis responsible for symptoms can restore local blood flow, but prevention of future events also depends on controlling exposures that affect the entire arterial tree.
The strongest causal evidence concerns atherogenic apoB-containing lipoproteins. Genetic studies, prospective observations, and therapeutic trials consistently demonstrate that greater exposure to LDL increases atherosclerotic events and that lowering LDL reduces them. LDL cholesterol reflects the mass of cholesterol carried by these particles, whereas apoB provides a measure of the total number of atherogenic particles. This distinction matters when particles are relatively cholesterol-depleted, as may occur in insulin resistance and hypertriglyceridemia: LDL-C that is not particularly high may coexist with an elevated apoB concentration. Plasma concentration, however, must be interpreted alongside duration of exposure and conditions that facilitate lipid entry into, and persistence within, the arterial wall.
The inherited component may be monogenic or polygenic. In familial hypercholesterolemia, defects in LDL receptor function or proteins that regulate its activity increase the lipid burden from birth, bringing forward the onset of lesions. Common variants, each with a smaller effect, instead contribute to the continuous distribution of risk in the population. A family history of early events may also reflect elevated Lp(a) and shared habits. Inheritance does not make an event inevitable, but it changes the starting point for prevention and may require interventions earlier than those suggested by ten-year risk alone.
VLDL and their remodeling products, together with chylomicron remnants small enough to cross the endothelial barrier, carry additional cholesterol that can potentially be retained in the intima. Plasma triglycerides therefore also signal the presence of altered lipoprotein metabolism: their concentration is not equivalent to the amount of cholesterol deposited in the plaque. Lipoprotein(a) is a particle containing apoB100 linked to apolipoprotein(a), with levels largely determined genetically. Its atherogenic properties are accompanied by the carriage of oxidized phospholipids and proinflammatory activities. Its causal relationship with atherosclerosis and calcific aortic stenosis does not justify considering it an established cause of every form of thrombosis, particularly venous thromboembolism.
Among other modifiable exposures, smoking impairs endothelial function, increases oxidative stress, and promotes platelet activation and thrombosis; elevated blood pressure subjects the wall to persistent mechanical loading and accelerates vascular damage. Diabetes combines lipoprotein abnormalities, hyperglycemia, protein glycation, oxidative stress, and immunometabolic dysfunction. Visceral adiposity contributes through insulin resistance, increased fatty acid delivery to the liver, VLDL secretion, altered adipokines, and inflammation. Chronic kidney disease adds endothelial dysfunction, uremic toxins, mineral metabolism abnormalities, and a bleeding risk that complicates antithrombotic prevention. These mechanisms interact and cannot be represented simply as independent contributions to a sum.
Age, biological sex, and family history modify the likelihood of disease; age also incorporates many years of exposure to modifiable factors. Chronic inflammatory diseases, HIV infection, certain previous obstetric conditions, social deprivation, physical inactivity, and pollution contribute to the overall assessment. For each factor, the strength of association, biological plausibility, and availability of interventions with documented clinical benefit must be distinguished. HDL-C provides an example: low concentrations may accompany high risk, but raising its level pharmacologically does not automatically prevent events. Inflammatory biomarkers can also be prognostic without being diagnostic tests for plaque or interchangeable treatment targets.
The arterial wall process begins with the entry and intimal retention of apoB particles. Interactions between lipoprotein components and matrix proteoglycans increase the time cholesterol remains within the wall. A preceding macroscopic tear of the endothelium is not necessary. The preferential distribution of lesions at bifurcations and curves reflects the role of disturbed flow: oscillatory shear stress favors proinflammatory endothelial signaling, while laminar flow promotes protective programs, including KLF2 activity and nitric oxide production. Vascular geometry therefore explains why the same plasma exposure produces highly uneven lesions along the arterial tree.
Retained lipoproteins undergo aggregation and enzymatic and oxidative modifications. Activated endothelium expresses adhesion molecules, including VCAM-1, and produces signals that favor monocyte and lymphocyte recruitment. The chemokine CCL2 and its receptor CCR2 participate in monocyte recruitment, without accounting for the full complexity of the pathways involved. In the intima, monocytes differentiate into macrophages that acquire lipids through scavenger receptors and other uptake mechanisms. The regulation of these pathways differs from that of the LDL receptor, so accumulation can continue even when the cell already contains substantial cholesterol. This gives rise to foam cells, a characteristic feature of early lesions.
Intracellular balance also depends on the ability to export cholesterol through transporters such as ABCA1 and ABCG1 to extracellular acceptors. When influx exceeds the capacity for mobilization, endoplasmic reticulum stress, lysosomal damage, and susceptibility to cell death increase. Cholesterol crystals and other damage signals can activate the NLRP3 inflammasome, promoting interleukin-1β maturation and the propagation of inflammation. These steps connect initial lipid deposition with a persistent immune response. HDL functions include cholesterol transport and additional biological activities; measuring HDL cholesterol alone does not directly measure the efficiency of those functions.
The adaptive immune response further modifies the lesion environment. Populations of T lymphocytes promote macrophage activation through cytokines such as interferon-γ, while others exert regulatory functions. B lymphocytes and antibodies may also have different roles according to the cell subtype and antigen involved. Atherosclerosis should therefore not be described as a uniform inflammatory response or as an infection of the arterial wall. Clonal hematopoiesis associated with somatic mutations, for example in TET2 or DNMT3A, can amplify certain inflammatory pathways and is associated with increased cardiovascular risk; its systematic identification, however, is not a routine step in diagnosing atherosclerosis.
Smooth muscle cells from the media migrate into and proliferate within the intima, changing their gene expression programs. Some produce extracellular matrix and support the fibrous cap; others adopt phenotypes that accumulate lipids or participate in mineralization. Consequently, not all foam cells derive from macrophages, and not all smooth muscle cell activities have the same significance. Collagen synthesis contributes to cap strength; proteases produced by inflammatory cells and reduced smooth muscle cell viability may weaken it. Lesion stability depends on the balance between matrix production and degradation, as well as local mechanical stresses.
As the disease progresses, clearance of apoptotic cell bodies by efferocytosis becomes inefficient. Uncleared material undergoes secondary necrosis and contributes to the lipid-rich necrotic core. Atheroma growth increases the oxygen diffusion distance and may promote neovascularization from the vasa vasorum. Plaque neovessels are fragile and permeable; their rupture introduces erythrocytes, cholesterol-rich membranes, and heme products, increasing lesion volume and oxidative stress. Intraplaque hemorrhage is therefore a mechanism of progression distinct from luminal thrombosis, although the two processes may coexist.
Plaque changes the vessel through remodeling, stenosis, and loss of normal vasomotor regulation. Outward expansion may initially preserve the lumen; in other lesions, remodeling is constrictive. When flow reserve becomes insufficient, increased tissue demand causes ischemia even if resting perfusion remains adequate. The severity and length of stenoses, serial lesions, downstream resistance, perfusion pressure, and collateral circulation modify the functional impact. Thus, the percentage of anatomical narrowing alone does not represent clinical severity. Oxygen demand, compensatory capacity, and tolerance of reduced oxygen supply differ between an ischemic limb, the myocardium, and the intestine.
Loss of surface integrity exposes a thrombogenic structure to circulating blood. Collagen, tissue factor, and local mediators activate platelets and coagulation, generating thrombin and fibrin. The thrombus may occlude the vessel or release material downstream; if it remains small and becomes organized, it may be incorporated into the plaque, increasing its thickness without a recognized clinical event. Atherothrombosis therefore depends on the interaction between the lesion, circulating blood, and hemodynamic conditions. An acute event does not necessarily require a previously critical stenosis, whereas a very severe stenosis may remain stable for a long time if the surface retains its integrity and collateral perfusion is sufficient.
Fatty streaks are early accumulations of lipid-containing cells and may appear long before clinical manifestations. Not all progress to complicated atheromas. Progression to advanced lesions involves extracellular lipid deposition, expansion of the matrix, and formation of a necrotic core. A fibroatheroma is organized around this core, which is separated from the blood by a cap of variable thickness and composition. Predominantly fibrous plaques, lipid-rich lesions, and densely calcified structures may occur simultaneously in the same patient. Histological classification describes these features but does not establish a mandatory, identical sequence for every arterial segment.
In plaque rupture, a breach in the cap exposes the core to the blood. A large core, a thin cap, and marked inflammatory infiltration are features associated with risk, not a certain prediction of rupture. The concept of thin-cap fibroatheroma derives mainly from coronary pathology; the microscopic thresholds defined in that setting should not automatically be applied to the carotid arteries or other vascular territories. Vulnerability also depends on lesion shape, stress concentration points, collagen distribution, and reparative activity. Identifying a thin cap on imaging therefore does not make it possible to assign a certain date or individual probability to a future event.
Superficial erosion causes thrombosis on a surface that has lost its normal endothelial lining while the fibrous cap remains intact. The plaques involved may contain more matrix and smooth muscle cells and be less dominated by a large necrotic core. Neutrophils, the extracellular structures they release, and changes in flow participate in the biology of erosion. A third, less common mechanism is an eruptive calcified nodule, in which mineral fragments protrude toward the lumen and disrupt the surface. The more detailed characterization of these phenotypes derives from coronary arteries and does not justify attributing the same frequencies to all arteries.
Calcification is a process regulated by cells and matrix, not merely passive precipitation of salts. Microscopic deposits in a cap may alter its mechanical stress; extensive confluent calcifications may instead accompany more chronic lesions and stabilization processes. This heterogeneity explains why greater calcium density during lipid-lowering treatment does not necessarily imply biological worsening. The overall coronary calcium burden remains a prognostic marker of exposure and disease burden, but its increase on serial measurements is not a reliable indicator of statin treatment failure. In peripheral arteries, moreover, intimal calcium must be distinguished from medial calcium, which can make the vessel noncompressible without indicating the severity of stenosis.
Healing of superficial damage and nonocclusive thrombi produces successive layers of organized tissue. This limits contact between the blood and thrombogenic material but may contribute to plaque growth. Another mechanism of acceleration is intraplaque hemorrhage, which is particularly important in characterizing carotid lesions. Atheromatous burden may therefore increase discontinuously, through phases of activity and repair. Complex aortic atherosclerosis may be associated with ulcerations and mobile components: when an ulcer penetrates beyond the intima, the concern is no longer limited to embolization or stenosis but also includes the structural stability of the aortic wall.
Research has progressively shifted from identifying the “vulnerable plaque” alone to assessing the high-risk patient. Many lesions with unfavorable features do not cause an event during the observation period, whereas numerous complications arise in people with a high overall disease burden and multiple vascular territories affected. Morphology retains value, especially for identifying the culprit lesion or planning a procedure, but preventive strategy must address the entire disease. The reduction in plaque volume may be modest even when treatment substantially reduces events: lipid influx, inflammatory activity, and plaque composition change, not just lumen diameter.
History-taking should begin with the reason for assessment: newly developed symptoms, progressive loss of independence, a previous ischemic event, or an incidental finding. The absence of symptoms does not exclude extensive lesions, particularly when the patient is physically inactive or has neuropathy. For each symptom, onset, duration, location, triggers, response to rest, and recent changes should be established. The first step is to recognize any acute ischemia, which requires urgent care and cannot be managed through a routine screening program or calculation of future risk.
For the coronary circulation, clinicians should ask about chest pressure or heaviness on exertion, radiation to the arms, jaw, or back, dyspnea, and reduced exercise tolerance. A stable symptom threshold suggests a chronic syndrome; symptoms occurring at rest, lasting a long time, or worsening rapidly increase suspicion of an acute event. Dyspnea, nausea, sweating, or malaise may predominate over pain, and the presentation may involve few symptoms. Previous myocardial infarctions, angioplasty procedures, or bypass operations do not complete the history: the subsequent course, medications taken, and any development of signs of heart failure or arrhythmia must also be reconstructed.
In the cerebrovascular territory, focal deficits are central: loss of strength or sensation on one side of the body, speech or language disturbances, monocular visual loss, and other symptoms consistent with a vascular territory. Complete resolution does not remove the urgency, because a transient ischemic attack may precede a stroke. A carotid plaque can cause embolization even without extreme obstruction; however, not every neurological event in a patient with carotid atherosclerosis originates from that plaque. Atrial fibrillation, small-vessel disease, and other embolic sources must remain in the differential diagnosis. Isolated dizziness or presyncope does not establish a carotid origin.
In the lower limbs, claudication consists of reproducible muscular discomfort during walking that resolves with rest; its location provides some indication, with limitations, of the level of disease. Walking distance, pace, uphill walking, actual activity, and coexisting joint limitations should be recorded. Rest pain in the foot, especially at night, nonhealing lesions, or gangrene suggest chronic limb-threatening ischemia. Sudden pain with coldness and loss of sensation or strength, by contrast, suggests acute ischemia. Diabetic neuropathy can reduce pain even when perfusion is severely compromised, making foot inspection particularly important.
Involvement of visceral arteries may present with abdominal pain after meals, reduced food intake, and weight loss; severe acute pain requires consideration of mesenteric ischemia, particularly when it seems disproportionate to the initial abdominal findings. Atherosclerotic renal artery stenosis may be associated with difficult-to-control hypertension, worsening kidney function and, in selected patients, episodes of pulmonary edema. These presentations are nonspecific, and finding a stenosis does not automatically establish its causal role. Upper-limb involvement may cause fatigue with use, claudication, and blood pressure differences; a subclavian steal presentation requires correlation between anatomy, flow, and symptoms.
Once symptoms have been characterized, the history should cover current and cumulative smoking exposure, lipid values before treatment, blood pressure trends, diabetes, kidney function, physical activity, diet, and family history. An especially early event warrants attention to inherited disorders and Lp(a). Medications, doses, tolerability, adherence, and recent interruptions should be checked specifically. Coexistence of disease in two or more territories defines a polyvascular phenotype, indicating greater systemic exposure and a worse prognosis than involvement of a single territory.
Physical examination begins with general condition, blood pressure, heart rate and rhythm and, when needed, oxygenation and signs of hypoperfusion. Measuring blood pressure in both arms is useful at the initial assessment and may suggest a proximal lesion, although it is not diagnostic. Cardiac and pulmonary auscultation, assessment for congestion, and neurological examination are guided by the clinical presentation. Pulses are palpated in sequence and compared between sides; bruits, temperature differences, pallor on elevation, dependent rubor, trophic changes, ulcers, and necrosis are sought. Bruits indicate turbulence, not a reliable measurement of stenosis, and may be absent in a very severe lesion.
In a foot at risk, lesion location and depth, infection, deformity, sensation, and footwear are evaluated. Edema can interfere with pulse palpation, which does not replace hemodynamic measurements when clinical suspicion is significant. Tendon xanthomas or corneal arcus developing at an early age may suggest inherited dyslipidemia but do not quantify plaque burden. A normal physical examination remains compatible with atherosclerosis: the conclusion of the consultation should formulate a precise clinical question, distinguishing detection of subclinical disease from investigation of ischemia or characterization of an already suspected complication.
There is no single set of international diagnostic criteria applicable to atherosclerosis in every vascular territory. According to the ESC guidelines on chronic coronary syndromes and peripheral arterial and aortic diseases, investigations should document the lesion in the relevant territory and establish whether it explains symptoms or produces functional consequences. Three findings must be kept distinct: presence of plaque, degree of stenosis, and hemodynamic significance. A test may provide information on one of these without answering the others. Histology can confirm the nature of a lesion in surgical or autopsy material but is not normally required for clinical diagnosis.
The diagnostic pathway changes immediately when there are signs of an emergency. Suspicious chest pain requires ECG and troponin testing according to acute coronary syndrome algorithms; sudden neurological deficits require urgent cerebral and vascular imaging; a cold limb with sensory-motor deficits needs immediate vascular assessment. Troponin demonstrates myocardial injury, not atherosclerosis directly, and an elevation must be interpreted alongside evidence of ischemia. Similarly, a cerebral infarct on imaging does not, by itself, establish an atherosclerotic mechanism. In these settings, timely investigation of the complication takes precedence over complete reconstruction of chronic risk.
In a stable patient, initial tests include a lipid profile, glucose or HbA1c depending on the context, creatinine with eGFR, and further tests justified by comorbidities and treatment. Non-HDL cholesterol, calculated by subtracting HDL-C from total cholesterol, describes the cholesterol carried by all atherogenic particles; apoB is particularly useful in cases of discordance, diabetes, or elevated triglycerides. Measuring Lp(a) at least once in adulthood contributes to risk characterization. There is no universally reliable conversion between mg/dL and nmol/L for Lp(a), owing to isoform variability. None of these tests alone demonstrates a plaque, and a favorable lipid profile during treatment does not negate an already documented anatomical diagnosis.
When lower-limb artery disease is suspected, the ankle-brachial index is a first-line investigation, obtained by comparing systolic pressures at the ankles and arms using a standardized technique. A value ≤0.90 indicates peripheral artery disease in the appropriate context. Elevated values, particularly above 1.40, may reflect noncompressible arteries and do not exclude disease. In this situation, common in diabetes and kidney disease, toe pressure and the toe-brachial index are useful, together with Doppler waveform assessment. If symptoms occur only during exercise and the resting index is normal or borderline, post-exercise measurement may clarify the suspicion. The index does not directly quantify the viability of an ulcer and does not exclude every cause of distal ischemia.
Duplex ultrasonography characterizes the wall, lumen, and blood flow velocities in accessible arteries. In carotid and peripheral territories it can identify plaques and narrowings and guide subsequent planning. Estimation of stenosis depends on the protocol, technical quality, and criteria validated for the territory concerned. Calcification, obesity, proximal lesions, or particular hemodynamic conditions may limit its accuracy. A simple increase in intima-media thickness is not equivalent to a focal plaque; it should not automatically be converted into a diagnosis of clinically significant atheromatosis. When an intervention depends on lesion quantification, confirmation with a second imaging modality may be necessary.
CT angiography defines location, extent, calcification, lumen, and anatomical relationships; MR angiography provides an alternative in selected contexts, with different limitations. The choice takes account of kidney function, contrast agents, radiation, implanted devices, artifacts, and the clinical question. In suspected acute mesenteric ischemia, CT angiography is central and should not be delayed by investigations that will not resolve the diagnostic question. In renal artery stenosis, imaging must be integrated with blood pressure trends, parenchymal function, and clinical scenarios that make a benefit from revascularization plausible. An incidental narrowing alone is not an indication for stent placement.
For coronary arteries, CT angiography can demonstrate calcified and noncalcified plaques and grade obstruction in patients selected according to clinical probability. The coronary calcium score, by contrast, measures only the calcified component and is mainly used to refine preventive decisions in people without known clinical disease. A score of zero makes a substantial calcified burden less likely but does not exclude noncalcified plaques, particularly in younger people, and does not replace assessment of suspicious symptoms. Functional stress tests detect ischemia; a negative result can coexist with nonobstructive atherosclerosis. Invasive coronary angiography is reserved for settings in which the probability of disease, severity of symptoms, risk, or therapeutic need justifies it.
When an intermediate coronary stenosis is investigated, physiological measures such as FFR and iFR can establish its functional significance, while IVUS and OCT analyze the vessel wall, composition, and features useful for the procedure. These are not population-wide screening tools. In the aorta, ultrasound, CT, MRI, and transesophageal echocardiography have complementary indications: the latter can examine thoracic aortic plaques when investigating an embolic source, while CT and MRI better define the extent and complications involving the wall. Interpretation of morphology always requires clinical context because a complex plaque may be an associated finding rather than necessarily the cause of the observed event.
The differential diagnosis includes vasculitis, fibromuscular dysplasia, dissections, cardiac embolism, nonatherosclerotic thrombotic diseases, and vascular compression. Lesion distribution, age, systemic signs, and the appearance of the vessel wall help distinguish them. In the limbs, lumbar spinal stenosis, neuropathy, and musculoskeletal disorders can mimic claudication; in the heart, vasospasm and microvascular dysfunction can produce ischemia without epicardial obstruction. The presence of risk factors increases pretest probability but does not remove the need to consider alternative diagnoses. Immunological or thrombophilia investigations should be ordered when there is a specific clinical question, not as a standard panel for every plaque.
Once the disease is confirmed, further investigations establish its extent and organ damage. Ventricular function after myocardial ischemia, the size and location of cerebral lesions, perfusion and tissue integrity in the foot, kidney function, and functional capacity modify prognosis and treatment. The search for involvement of other territories is guided by symptoms, examination findings, and the expected consequences of the result; a diagnosis in one location does not automatically require whole-body CT or multiple angiograms. The final diagnostic description should state the vascular territory, anatomical severity, any ischemia, complications, and systemic context, so that the word “atherosclerosis” alone does not replace clinically decisive information.
Treatment combines reduction of causal exposures, prevention of thrombosis when indicated, and correction of organ consequences. The ESC/EAS dyslipidemia guidelines, updated in 2025, and recommendations for individual vascular territories call for treatment intensity to be tailored to clinical severity and absolute risk. Clinically manifest atherosclerosis generally places a patient in a very-high-risk category; a small incidental subclinical finding, by contrast, requires more precise classification and does not automatically justify every secondary-prevention therapy. Symptoms, previous events, anatomical distribution, organ damage, and bleeding risk must be defined before medications and procedures are selected.
Smoking cessation is a priority intervention, supported by counseling and, when appropriate, pharmacological treatment of nicotine dependence. Passive exposure must also be considered, and relapse prevented. Dietary choices should favor vegetables, legumes, whole grains, nuts, and sources of unsaturated fats, replacing saturated fats and reducing foods high in salt and added sugars. Benefits derive from the overall dietary pattern and its sustainability, not from adding an isolated food or supplement. The Mediterranean diet has trial evidence for cardiovascular events in high-risk populations, but it does not replace medication when the magnitude of risk and lipid exposure warrant it.
Physical activity is adapted to functional capacity, ischemia, and comorbidities. For stable individuals, the goal is regular aerobic exercise combined with muscle-strengthening activity and less sedentary time; after a cardiovascular event, a structured rehabilitation program is particularly useful. In lower-limb artery disease, supervised exercise improves walking capacity through muscular and functional adaptations, even without eliminating the stenosis. Ischemic foot lesions, infection, or limb-threatening ischemia, however, require an individualized program: indiscriminately prescribing walking through pain is not appropriate at every stage of disease.
Lowering atherogenic lipoproteins is the principal treatment targeting the arterial wall disease process. In very-high-risk clinical disease, the European target is LDL-C <55 mg/dL together with a reduction of at least 50% from baseline. For high-risk patients the target is <70 mg/dL and at least a 50% reduction; lower-risk categories have different targets. In the event of a second vascular event within two years while receiving maximally tolerated treatment, a target of <40 mg/dL may be considered. These levels guide treatment strategy but do not represent a biological threshold beyond which risk disappears. The reduction in events is related to both the magnitude of LDL-C lowering and the length of time it is maintained.
A high-intensity statin, or the maximum tolerated dose, usually forms the basis of treatment. HMG-CoA reductase inhibition lowers hepatic cholesterol and increases LDL receptor expression, accelerating removal of particles from plasma. At appropriate doses, atorvastatin and rosuvastatin can achieve reductions of approximately 50% or more, with individual variation. Ezetimibe reduces intestinal cholesterol absorption through NPC1L1 and is added when a statin does not achieve the target or when a large shortfall from the target is expected from the outset. In patients following acute coronary syndrome, early intensification during hospitalization prevents months of inadequate treatment while risk remains high.
Monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, increase LDL receptor availability by preventing PCSK9-mediated degradation. The additional lipid reduction is substantial, and an event reduction has been documented in secondary prevention. Bempedoic acid acts upstream of HMG-CoA reductase by inhibiting ATP-citrate lyase; it is an option particularly when statin tolerability or failure to achieve the target requires other combinations. CLEAR Outcomes demonstrated a reduction in events in statin-intolerant patients, while hyperuricemia and gout warrant attention. Inclisiran reduces hepatic PCSK9 synthesis through RNA interference and offers infrequent dosing: its efficacy in lowering LDL-C must be distinguished from direct evidence of improved cardiovascular outcomes, which is being assessed in dedicated trials.
Managing intolerance requires assessing the timing of symptoms, other causes, interactions, and possible alternatives in drug or dose. Permanently discontinuing all treatment on the basis of a single episode may leave a high-risk person unprotected. Transaminases are assessed in the appropriate context; creatine kinase testing is mainly indicated in the presence of muscle symptoms or specific risk, not for indiscriminate monitoring of every asymptomatic person. The modest increase in diabetes risk associated with statins must be weighed against the cardiovascular benefit, which remains clearly favorable in patients with an appropriate indication. Very severe inherited forms may require specialist therapies, including those independent of the LDL receptor, or lipoprotein apheresis.
The risks associated with triglycerides and Lp(a) should not be treated as merely another form of LDL-C-related risk. In selected high- or very-high-risk patients with persistent hypertriglyceridemia despite statin treatment, icosapent ethyl may reduce events; this result cannot be extrapolated to ordinary omega-3 mixtures or over-the-counter supplements. Fibrates and other treatments have specific indications, particularly when severe hypertriglyceridemia poses a risk of pancreatitis, and do not replace LDL-C lowering. For elevated Lp(a), intensive control of other risk determinants is essential; drugs targeting apo(a) production require separate assessment of biomarker reduction, clinical outcomes, and approved indications. A promising biochemical effect alone does not demonstrate fewer myocardial infarctions.
Blood pressure control reduces loading on the vessel wall and the risk of events. The 2024 ESC guidelines propose a systolic blood pressure of 120–129 mmHg for many treated adults if well tolerated, with individualization in the presence of orthostatic hypotension, frailty, very advanced age, or limited life expectancy. Achieving the target should not come at the cost of hypoperfusion or disabling symptoms. In diabetes with cardiovascular disease, GLP-1 receptor agonists and SGLT2 inhibitors with proven benefits have a role extending beyond glucose lowering alone; their selection and combinations also depend on heart failure and kidney function. Obesity warrants specific treatment: SELECT documented a cardiovascular benefit of semaglutide in a population with cardiovascular disease and overweight or obesity without diabetes, but this does not make all weight-loss drugs automatically equivalent.
Antithrombotic therapy requires a clear distinction between clinical disease and a subclinical finding. Aspirin or other antiplatelet agents are indicated in numerous secondary-prevention settings, whereas the presence of risk factors alone or a small asymptomatic plaque does not establish a favorable benefit-to-bleeding balance. Following acute coronary syndrome or revascularization, drug choice and duration of dual antiplatelet therapy depend on the vascular territory, procedure, ischemic risk, and bleeding risk. Treatment of a noncardioembolic stroke follows specific neurological indications; if the source is atrial fibrillation, the anticoagulant strategy addresses a different mechanism. It is incorrect to extend an antithrombotic combination indefinitely merely because atherosclerosis is chronic.
In some people with high-risk coronary or peripheral artery disease and without a high bleeding risk, the combination of aspirin and rivaroxaban 2.5 mg twice daily reduces cardiovascular events and, in appropriate settings, limb ischemic events. This vascular dose is not equivalent to the dose used to prevent embolism from atrial fibrillation or treat venous thromboembolism. Selection requires exclusion of concurrent indications for different anticoagulant doses and assessment of kidney function, previous bleeding, and other contraindications. The advantage of greater ischemic protection must be weighed against the greater number of bleeding events observed in trials.
Modulation of inflammation has provided clinical evidence of its role in the disease. CANTOS showed that IL-1β blockade can reduce events in a selected population, but canakinumab is not a routine atherosclerosis treatment. Low-dose colchicine yielded favorable results in chronic coronary disease in LoDoCo2 and is considered for selected patients in European recommendations. The CLEAR trial of early use after myocardial infarction, published in 2025, did not reduce its primary endpoint, however: benefit cannot be generalized to every stage or vascular territory of the disease. Kidney and liver function, interactions involving CYP3A4 and P-glycoprotein, and gastrointestinal tolerability affect safety. Not all anti-inflammatory drugs produce the same biological or clinical effects.
Symptom control requires additional therapies according to the vascular territory. For angina, beta-blockers, calcium channel blockers, nitrates, and other medications are selected according to heart rate, blood pressure, ventricular function, and ischemic mechanism. Their ability to relieve symptoms does not necessarily correspond to a prognostic benefit in every patient. In peripheral artery disease, claudication treatment combines structured exercise and medical therapy; symptomatic drugs have their own indications and contraindications and do not replace cardiovascular protection. When tissue loss is present, management includes perfusion, wound care, pressure offloading, infection treatment, and multidisciplinary assessment. Simply reopening an artery may be insufficient if infection, repeated trauma, or irrecoverable tissue damage persists.
Revascularization is proposed when there is a defined clinical objective. In emergencies, it restores threatened perfusion; in chronic disease, it may improve refractory symptoms or prognosis in specific anatomical patterns and populations. Coronary PCI and bypass surgery, carotid endarterectomy or stenting, and peripheral procedures have different indications. A symptomatic carotid lesion, limb-threatening ischemia, and an incidental stenosis are not equivalent scenarios. The choice must integrate operative risk, duration of benefit, the possibility of restoring useful flow, and patient preferences. In atherosclerotic renal artery stenosis, medical therapy is fundamental and intervention is reserved for selected situations, without assuming a universal benefit.
After treatment, clinical follow-up assesses symptoms, independence, adherence, and attainment of goals. The lipid profile is reassessed after starting or intensifying therapy, usually within a few weeks, and subsequently according to stability and need. Imaging follow-up depends on the vascular territory and procedure: repeating every modality at fixed intervals in all patients is unnecessary. Recurrent symptoms, loss of functional capacity, or new skin lesions have different implications from a minor incidental change on imaging. Prognosis depends on disease extent, previous events, organ function, diabetes, kidney function, and treatment continuity. Risk falls even without disappearance of plaques, but it is not eliminated by normalization of a single measurement.
Complications primarily follow two pathways, which often overlap: progressively reduced perfusion and sudden formation or embolization of thrombotic material. Chronic stenosis limits flow reserve and may reduce exercise capacity, tissue nutrition, and independence. A lesion that grows through incorporation of silent thrombi may become a chronic occlusion; collateral development sometimes alleviates symptoms but does not guarantee normal perfusion on exertion. Damage depends on the vascular territory and cannot be ranked by a single frequency applicable to all patients with atherosclerosis.
Coronary atherothrombosis can cause myocardial infarction, the extent of which depends on the duration of occlusion, collateral flow, and speed of reperfusion. Loss of myocardium causes pump failure, potentially progressing to shock; electrical instability promotes ventricular tachycardia or fibrillation and sudden death. Necrosis may damage papillary muscles, the septum, or the free wall, causing acute mitral regurgitation, a ventricular septal defect, or cardiac tamponade. Later, scarring and remodeling may sustain chronic heart failure, functional mitral regurgitation, and reentrant arrhythmias. A thrombus formed in an akinetic ventricle can embolize through a mechanism distinct from the initial arterial plaque.
In the cerebral circulation, ischemic stroke may result from emboli originating from an extracranial or intracranial plaque, or from insufficient flow in the presence of severe stenoses and inadequate collateral circulation. Consequences include motor disability and disturbances of language, swallowing, and cognition, depending on lesion location and extent. A transient ischemic attack signals an early risk of recurrence even when it leaves no persistent deficits. Recurrent events may accumulate disability and increase the need for assistance; prevention must therefore address the actual mechanism of the event, avoiding automatic attribution of every stroke to a plaque that is present but not responsible.
In the lower limbs, chronic limb-threatening ischemia can lead to persistent pain, ulcers, and gangrene. Insufficient perfusion limits oxygen delivery and healing capacity; neuropathy, trauma, and infection worsen damage, particularly in diabetes. Amputation may result, with loss of independence and a further increase in cardiovascular risk. Acute thrombosis superimposed on preexisting artery disease may instead cause rapid deterioration in limb viability. Motor impairment signals a particularly serious situation. After reperfusion of a limb that has been ischemic for a prolonged period, compartment syndrome, rhabdomyolysis, hyperkalemia, and kidney injury may develop; these consequences of ischemic injury and reperfusion require dedicated monitoring.
Chronic mesenteric ischemia may cause malnutrition because patients reduce their meals to avoid pain; acute thrombosis may lead to intestinal infarction, loss of the mucosal barrier, sepsis, and multiorgan failure. In the renal circulation, hypoperfusion and parenchymal damage may sustain hypertension and reduced kidney function, although causal attribution requires caution when other kidney diseases coexist. Aortic disease can generate emboli to the brain, kidneys, intestines, or limbs. A penetrating atherosclerotic ulcer may be complicated by intramural hematoma or rupture; aortic aneurysm is frequently associated with atherosclerosis and shared risk factors, but has a pathogenesis that should not be reduced to simple plaque expansion.
Cholesterol crystal atheroembolism results from the release of material from plaques, often aortic, leading to small-vessel occlusion and an inflammatory response. It may occur spontaneously or after vascular manipulation and cause kidney injury, livedo reticularis, and digital ischemia even when peripheral pulses remain palpable. This presentation differs from large-artery embolism and venous thrombosis. Onset may be delayed after a procedure, and multiorgan involvement requires systemic assessment. Finding an ischemic toe therefore does not automatically identify the location of the source or the appropriate antithrombotic treatment.
Treatments have their own complications: bleeding from antithrombotic agents, adverse drug effects, kidney injury or other procedural consequences, stent restenosis and thrombosis, bypass graft occlusion, and infection involving implanted materials. Early restenosis and progression of native atherosclerosis are not equivalent processes; late forms of neoatherosclerosis may also occur in devices and grafts. The risk of recurrent events remains particularly high after a first event and in polyvascular disease. Surveillance must therefore integrate local complications with protection of the patient as a whole, maintaining prevention even when a procedure has completely resolved the original symptom.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.